Medical Device Manufacturing Transfer: Steps, Risks, and What to Validate
Written by
Arterex Medical
Published on
November 18, 2026
Read time
6 minute read
In this guide, a manufacturing transfer means moving production of an existing medical device to a new site or supplier. It is closely tied to design transfer, the controlled handoff of design outputs from research and development to manufacturing, and the two terms are often mixed up. This guide covers the steps, the common pitfalls, and what needs to be validated, drawing on ISO 13485:2016, the FDA’s Quality Management System Regulation, and published industry guidance.
Design transfer vs. manufacturing transfer
Design transfer is the controlled handoff of design outputs, such as specifications, drawings, and quality control methods, from R&D to manufacturing. ISO 13485:2016 clause 7.3.8 requires documented procedures for it[3]. Under that clause, outputs must be verified as suitable for manufacturing, production capability must be shown, and the results must be recorded[4].
In the United States, the FDA’s Quality Management System Regulation (QMSR) took effect on February 2, 2026. It incorporates ISO 13485:2016 by reference into 21 CFR Part 820[1]. Design and development requirements are reached through §820.10, which points to ISO 13485 clause 7.3. The older design controls section (§820.30) is now marked [Reserved], and the old process validation section (§820.75) no longer appears[2].
A manufacturing transfer applies the same controls to a product that is already in production. Relocating a site or a line triggers a new design transfer round under change control, and treating it as a routine move is listed among the common pitfalls[3].
Why manufacturers transfer production
The reasons depend on the program. One cited on Arterex’s transfer page is meeting cost targets by moving production to lower-cost regions[5]. Whatever the reason, the device manufacturer remains responsible for outsourced processes[3] and keeps ultimate regulatory responsibility when a contract manufacturer is used[4].
The steps of a manufacturing transfer
1. Evaluate the product and the process
Planning starts once product specifications are finalized. Key early activities include process FMEA, identifying critical parameters, developing test methods and work instructions, and training operators[3]. Manufacturing constraints should be considered early, and industrialization, engineering, and production teams should be involved from the start[3]. One pitfall to avoid is confusing technical feasibility, which a prototype demonstrates, with industrial feasibility, which means repeatable production at volume[3].
2. Confirm the documentation is complete
The Device Master Record (DMR) is the main output of a transfer. Under QMSR terminology it maps to the Medical Device File (MDF)[4]. A complete record typically covers:
- Device specifications and production process specifications
- Assembly and work instructions
- Bill of materials
- Packaging and labeling, including UDI placement
- Acceptance criteria for incoming, in-process, and final inspection
- Equipment and test specifications
- Maintenance and servicing procedures
- Software build identifiers[4]
All design and manufacturing requirements, including drawings, specifications, control plans, and procedures, must be documented, kept current, and formally approved. Any redesign requires change control and an assessment of its impact[3]. A frequent problem is treating design outputs as the final DMR when production documents, such as logistics requirements and supplier change-control agreements, are still missing[3].
3. Qualify the new site and its suppliers
The manufacturer must monitor the supplier’s equipment qualification, process validation, and document versions, and write change-control requirements into the quality agreement[3]. Suppliers are qualified under ISO 13485 clause 7.4.1, which involves establishing quality agreements, verifying capability, and defining incoming acceptance criteria[4].
4. Validate the process at the new site
Process validation falls under ISO 13485 clause 7.5.6[3]. The standard approach has three stages[4]:
- Installation Qualification (IQ): confirms equipment is installed per specifications, utilities and environment are in place, and instruments are calibrated.
- Operational Qualification (OQ): shows the equipment operates within design limits, defines the process window, and includes worst-case and challenge testing.
- Performance Qualification (PQ): shows consistent output under routine conditions, typically across at least three consecutive batches, with reproducibility across operators and shifts.
Documentation includes a validation master plan, pre-approved protocols, and reports, and revalidation is required when changes could affect the validated process[4]. Qualification and process validation are different: qualification shows equipment performance, while process validation shows consistent production[3]. Validation must use product representative of the final device, made with the definitive production means. Early prototypes confirm principles, while pilot or pre-series lots prove repeatability, and biocompatibility testing needs samples in their final commercial configuration[3].
5. Hold a transfer readiness review
A final design transfer review before production covers DMR completeness, validation status, supplier readiness, process FMEA, training, and closure of action items. The outcome is approved, approved with conditions, or not approved[4].
Where manufacturing transfers go wrong
Two of the sources describe the same failure points:
- Starting too late, which forces redesign and revalidation[4]
- An incomplete DMR built from uncontrolled documents[4]
- Skipped or inadequate process validation[4]
- Poor supplier communication that omits functional context[4]
- No formal, approved design transfer procedure[4]
- Confusing design validation with process validation, or verification with validation[3]
- Treating a site or line relocation as routine, when it triggers a new design transfer round under change control[3]
Manufacturing transfer checklist
Procedures and planning
- Is there a formal, approved design transfer procedure?[4]
- Did transfer planning start during design, not after validation?[4]
Documentation
- Is the DMR (or MDF) complete and built from controlled documents?[4]
- Do production documents, including logistics and supplier change-control agreements, exist?[3]
Process validation
- Are IQ, OQ, and PQ protocols pre-approved?[4]
- Did PQ cover consecutive batches across operators and shifts?[4]
- Was validation done with the definitive production means and representative product?[3]
Suppliers
- Are suppliers qualified, with a quality agreement and defined incoming acceptance criteria?[4]
- Are change-control requirements written into the quality agreement?[3]
Risk, training, and records
Frequently asked questions
What is the difference between design transfer and manufacturing transfer?
Design transfer is the controlled handoff of design outputs from R&D to manufacturing[3]. In this guide, manufacturing transfer means moving production of an existing device to a new site or supplier. Relocating a site or line triggers a new design transfer round under change control[3].
Does moving production to a new site require revalidation?
Revalidation is required when a change could affect the validated process[4], and a site or line relocation triggers a new design transfer round under change control[3]. Confirm the exact scope for your device with your quality and regulatory teams.
How many batches does process performance qualification require?
PQ is typically run across at least three consecutive batches, with reproducibility shown across operators and shifts[4].
Who is responsible when a contract manufacturer is used?
The device manufacturer keeps ultimate regulatory responsibility[4] and remains responsible for outsourced processes[3].
When should transfer planning start?
During design, not after validation. Starting too late forces redesign and revalidation[4].
Do the FDA’s requirements still cite 21 CFR 820.30 and 820.75?
Not as separate sections. §820.30 is marked [Reserved] and §820.75 no longer appears. Design and development requirements are reached through §820.10 and ISO 13485 clause 7.3[2].
How Arterex Executes Manufacturing Transfers
Further reading
Arterex’s manufacturing transfers page describes product and process evaluation, engineering revisions and optimization, LEAN and Six Sigma, value engineering, and a sustaining engineering team[5].
Sources
Related posts
What To Know About Medical Device Manufacturing? Written by Arterex Medical Published on November 29, 2024 Read time 7 minute read What Is Medical
- Medical Device Manufacturing Transfer: Steps, Risks, and What to Validate
- Design transfer vs. manufacturing transfer
- Why manufacturers transfer production
- The steps of a manufacturing transfer
- Where manufacturing transfers go wrong
- Manufacturing transfer checklist
- Frequently asked questions
- How Arterex Executes Manufacturing Transfers
- Further reading
- Sources
